LAKE FOREST, Calif.--(BUSINESS WIRE)--STAAR Surgical Company (NASDAQ: STAA), the global leader in phakic IOLs with the EVO family of Implantable Collamer® Lenses (EVO ICL™) for vision correction, today reported results for the second quarter ended June 27, 2025. Second Quarter 2025 Financial Overview Net sales of $44.3 million down 55% Y/Y due to planned reduction of channel inventory in China Net sales excluding China of $39.0 million up 10% Y/Y Gross margin at 74.0% vs. 79.2% year ago due to
Related Questions
Is the company expecting any further supply chain disruptions or inventory adjustments in other markets?
Will management provide any guidance on sales velocity of EVO ICL post‑inventory reduction?
Did the company adjust its operating expense forecast for Q3 and Q4 2025?
Are there any changes to the gross margin outlook for the remainder of 2025?
What is the projected impact on net income and net profit margin for the full year?
How does the current valuation metrics (PE, EV/EBITDA) look after this earnings release?
What are the implications for STAA's share repurchase program or dividend policy?
How does the 10% YoY growth in net sales excluding China compare to regional competitors' performance?
What is the impact of the China inventory reduction on cash flow and working capital?
What is the revised revenue guidance for FY2025 given the 55% YoY decline in net sales?
Are there any updates on regulatory approvals or new product developments that could influence future sales?
How will the lower gross margin affect profitability and EPS guidance?
How might the inventory drawdown in China affect the company's market share in the Chinese vision correction market?
How many units of EVO ICL inventory are being reduced in China, and what is the expected timeline for replenishment?
What is the company’s plan to offset the China sales decline—e.g., new market expansion or product launches?